以岭药业
(002603)
| 流通市值：213.05亿 | | | 总市值：258.63亿 |
| 流通股本：13.76亿 | | | 总股本：16.71亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 5,968,384,714.01 | 4,074,750,595 | 2,439,783,832.76 | 7,830,737,438.74 |
| 营业总成本 | 4,666,906,759.89 | 3,172,624,664.1 | 1,941,982,482.08 | 6,149,554,601.93 |
| 其他经营收益 | | | | |
| 营业利润 | 1,321,843,163.62 | 916,325,401.34 | 499,741,266.75 | 1,623,431,472.75 |
| 利润总额 | 1,317,103,462.63 | 911,369,557.28 | 489,099,279.3 | 1,591,610,902.08 |
| 净利润 | 1,095,787,348.55 | 757,077,098.98 | 408,612,429.2 | 1,281,729,907.88 |
| 每股收益 | | | | |
| 其他综合收益 | -530,267.54 | -299,714.12 | 382,786.36 | -713,938 |
| 综合收益总额 | 1,095,257,081.01 | 756,777,384.86 | 408,995,215.56 | 1,281,015,969.88 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 6,067,387,509.7 | 5,744,209,594.02 | 5,785,791,884.73 | 5,206,141,683.31 |
| 非流动资产: | | | | |
| 非流动资产合计 | 8,085,329,259.99 | 8,239,722,828.62 | 8,392,139,621.5 | 8,468,856,813.64 |
| 资产总计 | 14,152,716,769.69 | 13,983,932,422.64 | 14,177,931,506.23 | 13,674,998,496.95 |
| 流动负债: | | | | |
| 流动负债合计 | 2,443,103,366.7 | 2,607,067,447.92 | 2,312,447,975.1 | 2,208,205,004.61 |
| 非流动负债: | | | | |
| 非流动负债合计 | 467,811,987.19 | 473,543,255.07 | 474,591,292.78 | 484,896,469.55 |
| 负债合计 | 2,910,915,353.89 | 3,080,610,702.99 | 2,787,039,267.88 | 2,693,101,474.16 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 11,249,144,441.06 | 10,910,748,327.4 | 11,398,333,808.01 | 10,989,102,712.08 |
| 股东权益合计 | 11,241,801,415.8 | 10,903,321,719.65 | 11,390,892,238.35 | 10,981,897,022.79 |
| 负债和股东权益合计 | 14,152,716,769.69 | 13,983,932,422.64 | 14,177,931,506.23 | 13,674,998,496.95 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 6,958,705,562.82 | 4,744,603,586.91 | 2,526,488,972.52 | 8,795,003,112.74 |
| 经营活动现金流出小计 | 5,349,947,945.13 | 3,564,840,219.2 | 1,915,779,157.99 | 7,018,494,734.27 |
| 经营活动产生的现金流量净额 | 1,608,757,617.69 | 1,179,763,367.71 | 610,709,814.53 | 1,776,508,378.47 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 3,306,698,401.41 | 2,172,568,603.74 | 814,679,962.9 | 1,497,642,892.99 |
| 投资活动现金流出小计 | 4,478,246,248.54 | 2,764,641,612.51 | 1,744,183,825.3 | 2,499,617,151.14 |
| 投资活动产生的现金流量净额 | -1,171,547,847.13 | -592,073,008.77 | -929,503,862.4 | -1,001,974,258.15 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | - |
| 筹资活动现金流出小计 | 841,216,058.1 | 840,786,036.51 | 2,320,329.25 | 513,633,146.95 |
| 筹资活动产生的现金流量净额 | -841,216,058.1 | -840,786,036.51 | -2,320,329.25 | -513,633,146.95 |
| 汇率变动对现金及现金等价物的影响 | -11,336.9 | 102,128.94 | 274,475.71 | -812,591.14 |
| 现金及现金等价物净增加额 | -404,017,624.44 | -252,993,548.63 | -320,839,901.41 | 260,088,382.23 |
| 期末现金及现金等价物余额 | 672,673,932.19 | 823,698,008 | 755,851,655.22 | 1,076,691,556.63 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -252,993,548.63 | - | 260,088,382.23 |
最新报告期：2026-10-30| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 代雯,唐庆雷,张云逸 | 0.92 | 1.09 | 1.26 | 2026-10-30 |
| 中金公司 | 夏璐,张琎,朱言音 | 0.85 | 0.94 | -- | 2026-10-29 |
| 中信建投 | 刘若飞,沈兴熙,贺菊颖 | 0.89 | 1.04 | 1.20 | 2026-09-06 |
| 中金公司 | 夏璐,张琎,朱言音 | 0.88 | 0.99 | -- | 2026-09-01 |
| 华泰证券 | 代雯,唐庆雷,张云逸 | 0.92 | 1.09 | 1.26 | 2026-08-31 |